STOCK TITAN

Emergent BioSolutions Announces Amendment to its Existing Credit Facility

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Emergent BioSolutions Inc. announces an amendment to its credit facility, providing an extended runway for executing its business plan and stabilizing its financial position. The company's president and CEO, Joe Papa, expressed optimism about the positive development and collaboration with the bank group. The upcoming first quarter 2024 financial results will be reported on May 1, 2024, along with key business updates and financial reviews.

Emergent BioSolutions Inc. annuncia una modifica alla sua linea di credito, offrendo maggior tempo per l'attuazione del suo piano aziendale e la stabilizzazione della sua posizione finanziaria. Il presidente e CEO dell'azienda, Joe Papa, ha espresso ottimismo riguardo a questo sviluppo positivo e alla collaborazione con il gruppo bancario. I risultati finanziari del primo trimestre del 2024 verranno pubblicati il 1° maggio 2024, insieme ad aggiornamenti importanti sull'azienda e revisioni finanziarie.
Emergent BioSolutions Inc. anuncia una enmienda a su facilidad de crédito, proporcionando un camino extendido para ejecutar su plan de negocios y estabilizar su posición financiera. El presidente y CEO de la compañía, Joe Papa, se mostró optimista sobre el desarrollo positivo y la colaboración con el grupo bancario. Los resultados financieros del primer trimestre de 2024 serán reportados el 1 de mayo de 2024, junto con actualizaciones importantes del negocio y revisiones financieras.
Emergent BioSolutions Inc.는 신용시설에 대한 개정을 발표하여 비즈니스 계획을 실행하고 재정적 위치를 안정화할 수 있는 더 많은 시간을 제공합니다. 회사의 회장이자 CEO인 Joe Papa는 긍정적인 발전과 은행 그룹과의 협력에 대해 낙관적이었습니다. 2024년 1분기 재무 결과는 2024년 5월 1일에 보고될 예정이며, 주요 사업 업데이트 및 재무 리뷰와 함께 발표됩니다.
Emergent BioSolutions Inc. annonce une modification de sa facilité de crédit, offrant une marge de manœuvre prolongée pour l'exécution de son plan d'affaires et la stabilisation de sa position financière. Le président et CEO de l'entreprise, Joe Papa, s'est montré optimiste quant à ce développement positif et à la collaboration avec le groupe bancaire. Les résultats financiers du premier trimestre 2024 seront communiqués le 1er mai 2024, accompagnés des mises à jour importantes sur les affaires et des revues financières.
Emergent BioSolutions Inc. kündigt eine Änderung seiner Kreditfazilität an, die einen erweiterten Spielraum für die Umsetzung seines Geschäftsplans und die Stabilisierung seiner finanziellen Lage bietet. Der Präsident und CEO des Unternehmens, Joe Papa, äußerte sich optimistisch über die positive Entwicklung und die Zusammenarbeit mit der Bankengruppe. Die Finanzergebnisse für das erste Quartal 2024 werden am 1. Mai 2024 berichtet, zusammen mit wichtigen Geschäftsaktualisierungen und Finanzüberprüfungen.
Positive
  • None.
Negative
  • None.

GAITHERSBURG, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced that it has entered into a “Consent, Waiver and Seventh Amendment” to its existing credit facility.

“In light of this amendment, Emergent now has an extended runway to execute on our go-forward business plan to stabilize our financial position,” stated Joe Papa, president and CEO of Emergent. “Our bank group continues to work with our management team in a constructive fashion, evidenced by this positive development.”

On May 1, 2024, Emergent will report its first quarter 2024 financial results via conference call, as well highlight key business updates, Q1 2024 financial review, and FY 2024 and Q2 2024 guidance.

About Emergent BioSolutions

At Emergent, our mission is to protect and enhance life. For 25 years, we’ve been at work defending people from things we hope will never happen—so we are prepared just in case they ever do. We provide solutions for complex and urgent public health threats through a portfolio of vaccines and therapeutics that we develop and manufacture for governments and consumers. We also offer a range of integrated contract development and manufacturing services for pharmaceutical and biotechnology customers. To learn more about how we plan to protect or enhance 1 billion lives by 2030, visit our website and follow us on LinkedInX, Instagram, Apple Podcasts and Spotify.

Safe Harbor Statement
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are forward-looking statements. We generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “goal,” “intend,” “may,” “plan,” “position,” “possible,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statements will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statements. Any forward-looking statement speaks only as of the date of this press release and, except as required by law, we do not undertake any obligation to update any forward-looking statement to reflect new information, events or circumstances.

There are a number of important factors that could cause our actual results to differ materially from those indicated by any forward-looking statements. Readers should consider this cautionary statement, as well as the risk factors and other disclosures included in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements.

Investor Contact:
Richard S. Lindahl
Executive Vice President, CFO
lindahlr@ebsi.com

Media Contact:
Assal Hellmer
Vice President, Communications
mediarelations@ebsi.com


FAQ

When did Emergent BioSolutions announce the amendment to its credit facility?

Emergent BioSolutions announced the amendment to its credit facility on April 30, 2024.

Who is the president and CEO of Emergent BioSolutions?

Joe Papa is the president and CEO of Emergent BioSolutions.

When will Emergent BioSolutions report its first quarter 2024 financial results?

Emergent BioSolutions will report its first quarter 2024 financial results on May 1, 2024.

What will be included in the report of Emergent BioSolutions' first quarter 2024 financial results?

The report will highlight key business updates, Q1 2024 financial review, and FY 2024 and Q2 2024 guidance.

Emergent BioSolutions Inc.

NYSE:EBS

EBS Rankings

EBS Latest News

EBS Stock Data

586.90M
52.40M
2.16%
69.96%
12.08%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
GAITHERSBURG